poisar

Stock

MannKind Corporation MNKD

$4.08+4.62%

Overview

MNKD market data

Price History

MNKD price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
213.15
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
$0.02
Diluted earnings per share over the trailing twelve months.
Beta
1.12
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.23 – $6.51
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.2K · P/B 4.03 · P/S 3.46.

Company news

10 captured
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney DiseaseBenzinga · Jul 24, 2026, 6:06 PM
MannKind shares are trading higher after the company announced it received FDA approval of its Furoscix ReadyFlow. Also, the company announced a $50 million private placement financing.Benzinga · Jul 24, 2026, 4:07 PM
MannKind Announces $50M Private Placement Financing, Closing Expected On Or About July 24Benzinga · Jul 24, 2026, 10:37 AM
MannKind Receives FDA Approval Of Its Furoscix ReadyFlow For Treatment Of Edema In Adults With Heart Failure Or Chronic Kidney DiseaseBenzinga · Jul 24, 2026, 10:33 AM
MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric PatientsBenzinga · Jun 23, 2026, 1:10 PM
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War EndsBenzinga · Jun 5, 2026, 12:10 PM
8-K filing — MANNKIND CORP (MNKD)SEC EDGAR · Jun 2, 2026, 12:00 PM
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric ApprovalGlobenewswire Inc · May 29, 2026, 6:15 PM
MannKind To Host Conference Call At 4:30 p.m. ET On May 29 To Discuss FDA Approval Of Pediatric Use Of AfrezzaBenzinga · May 29, 2026, 6:10 PM
MannKind Wins FDA Approval For Pediatric Use Of Inhaled Insulin Afrezza In Children Ages 6 And Older With DiabetesBenzinga · May 29, 2026, 4:35 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock